| 英文名稱 |
中文名稱 |
CAS號 |
操作 |
| FR-188582 |
189699-82-9 |
189699-82-9 |
詳細(xì)
|
| Pamicogrel |
帕米甘草 |
101001-34-7 |
詳細(xì)
|
| Neoseptin 3 |
1622863-21-1 |
1622863-21-1 |
詳細(xì)
|
| Bropirimine |
溴匹立明 |
56741-95-8 |
詳細(xì)
|
| Phenethyl ferulate |
阿魏酸苯乙酯 |
71835-85-3 |
詳細(xì)
|
| Phenidone |
菲尼酮 |
92-43-3 |
詳細(xì)
|
| Citronellol |
香茅醇 |
106-22-9 |
詳細(xì)
|
| DL-Norvaline |
DL-正纈氨酸 |
760-78-1 |
詳細(xì)
|
| NLRP3-IN-2 |
4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺 |
16673-34-0 |
詳細(xì)
|
| Benzyl butyl phthalate |
鄰苯二甲酸丁芐酯 |
85-68-7 |
詳細(xì)
|
| Pelargonidin chloride |
氯化花葵素 |
134-04-3 |
詳細(xì)
|
| Cridanimod |
吖啶酮乙酸 |
38609-97-1 |
詳細(xì)
|
| 2,5-Di-tert-butylhydroquinone |
2,5-二特丁基對苯二酚 |
88-58-4 |
詳細(xì)
|
| D-Kynurenine |
犬尿氨酸 |
13441-51-5 |
詳細(xì)
|
| 3-Indolepropionic acid |
吲哚-3-丙酸 |
830-96-6 |
詳細(xì)
|
| Hydroxychloroquine |
羥基氯喹 |
118-42-3 |
詳細(xì)
|
| RO8191 |
8-(1,3,4-OXADIAZOL-2-YL)-2,4-BIS(TRIFLUOROMETHYL)IMIDAZO[1,2-A][1,8]NAPHTHYRIDINE |
691868-88-9 |
詳細(xì)
|
| Methyl Salicylate |
水楊酸甲酯 |
119-36-8 |
詳細(xì)
|
| Sodium dichloroacetate |
二氯乙酸鈉 |
2156-56-1 |
詳細(xì)
|
| PD-161570 |
PD-161570;PF-1480232 |
192705-80-9 |
詳細(xì)
|
| HO-3867 |
HO-3867 |
1172133-28-6 |
詳細(xì)
|
| BP-1-102 |
4-(N-(4-環(huán)己基芐基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羥基苯甲酸 |
1334493-07-0 |
詳細(xì)
|
| SH5-07 |
1456632-41-9 |
1456632-41-9 |
詳細(xì)
|
| HJC0152 hydrochloride |
2-(2-氨基乙氧基)-5-氯-N-(2-氯-4-硝基苯基)苯甲酰胺鹽酸鹽 |
1420290-99-8 |
詳細(xì)
|
| STAT3-IN-1 |
STAT3-IN-1 |
2059952-75-7 |
詳細(xì)
|
| PF-06651600 |
利特昔替尼 |
1792180-81-4 |
詳細(xì)
|
| TX1-85-1 |
TX1-85-1 |
1603845-32-4 |
詳細(xì)
|
| PF-06263276 |
PF-06263276 (PF 6263276) |
1421502-62-6 |
詳細(xì)
|
| TP-3654 |
TP3654 |
1361951-15-6 |
詳細(xì)
|
| RG13022 |
RG-13022 |
136831-48-6 |
詳細(xì)
|
| TyK2-IN-2 |
2098466-94-3 |
2098466-94-3 |
詳細(xì)
|
| STAT5-IN-1 |
STAT5 Inhibitor |
285986-31-4 |
詳細(xì)
|
| INCB053914 phosphate |
CS-2873 |
2088852-47-3 |
詳細(xì)
|
| SMI-16a |
PIM1/2 KINASE INHIBITOR VI |
587852-28-6 |
詳細(xì)
|
| JAK3-IN-6 |
JAK3-IN-6 |
1443235-95-7 |
詳細(xì)
|
| FM-381 |
(E)-2-CYANO-3-(5-(1-CYCLOHEXYL-1,6-DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-2-YL)FURAN-2-YL)-N,N-DIMETHYLACRYLAMIDE |
2226521-65-7 |
詳細(xì)
|
| STAT5-IN-2 |
STAT5-IN-2 |
2111834-61-6 |
詳細(xì)
|
| inS3-54A18 |
328998-53-4 |
328998-53-4 |
詳細(xì)
|
| RSVA405 |
化合物RSVA 405 |
140405-36-3 |
詳細(xì)
|
| BMS-690514 |
(3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-F][1,2,4]三嗪-5-基]甲基]哌啶-3-醇 |
859853-30-8 |
詳細(xì)
|
| CGP52411 |
CGP 52411 |
145915-58-8 |
詳細(xì)
|
| HKI-357 |
HKI 357 |
848133-17-5 |
詳細(xì)
|
| AV-412 |
AV 412 |
451493-31-5 |
詳細(xì)
|
| AV-412 free base |
AV-412 |
451492-95-8 |
詳細(xì)
|
| Canertinib |
卡奈替尼 |
267243-28-7 |
詳細(xì)
|
| Pim1/AKK1-IN-1 |
N-[5-(4-氰基苯基)-1H-吡咯并[2,3-B]吡啶-3-基]-3-吡啶甲酰胺 |
1093222-27-5 |
詳細(xì)
|
| Pyrotinib Racemate |
1246089-97-3 |
1246089-97-3 |
詳細(xì)
|
| Pyrotinib dimaleate |
馬來酸吡咯替尼 |
1397922-61-0 |
詳細(xì)
|
| Theliatinib |
席栗替尼 |
1353644-70-8 |
詳細(xì)
|
| Fedratinib hydrochloride hydrate |
TG-101348 |
1374744-69-0 |
詳細(xì)
|
| Reslizumab |
RESLIZUMAB |
241473-69-8 |
詳細(xì)
|
| Nitroflurbiprofen |
158836-71-6 |
158836-71-6 |
詳細(xì)
|
| SC57666 |
158959-32-1 |
158959-32-1 |
詳細(xì)
|
| Atezolizumab |
阿特珠單抗 |
1380723-44-3 |
詳細(xì)
|
| Ustekinumab |
烏司奴單抗 |
815610-63-0 |
詳細(xì)
|
| Durvalumab |
德瓦魯單抗 |
1428935-60-7 |
詳細(xì)
|
| Benralizumab |
BENRALIZUMAB |
1044511-01-4 |
詳細(xì)
|
| Dupilumab |
度匹魯單抗 |
1190264-60-8 |
詳細(xì)
|
| ARRY-380 (analog ) |
ARRY-380 |
937265-83-3 |
詳細(xì)
|
| AZD4205 |
AZD4205 |
2091134-68-6 |
詳細(xì)
|
| MTX-211 |
MTX-211 |
1952236-05-3 |
詳細(xì)
|
| Epertinib hydrochloride |
EPERTINIB HYDROCHLORIDE |
2071195-74-7 |
詳細(xì)
|
| Momelotinib sulfate |
N-(氰基甲基)-4-[2-[[4-(4-嗎啉基)苯基]氨基]-4-嘧啶基]苯甲酰胺硫酸鹽(1:2) |
1056636-06-6 |
詳細(xì)
|
| (R)-Lisofylline |
1-(5-hydroxyhexyl)-3,7-dimethyl-purine-2,6-dione |
100324-81-0 |
詳細(xì)
|
| EGFR-IN-5 |
EGFR-IN-5 |
2225887-26-1 |
詳細(xì)
|
| Tyk2-IN-5 |
TYK2-IN-5 |
1797432-62-2 |
詳細(xì)
|
| TAS6417 |
齊帕勒替尼 |
1661854-97-2 |
詳細(xì)
|
| PD-089828 |
PD089828 |
179343-17-0 |
詳細(xì)
|
| Protosappanin A |
原蘇木素A |
102036-28-2 |
詳細(xì)
|
| G5-7 |
化合物JAK2 INHIBITOR G5-7 |
939681-36-4 |
詳細(xì)
|
| PKI-166 |
PKI 166 |
187724-61-4 |
詳細(xì)
|
| Tyrphostin AG30 |
酪氨酸磷酸化抑制劑 AG 30 |
122520-79-0 |
詳細(xì)
|
| PF-06700841 P-Tosylate |
CS-2860 |
2140301-96-6 |
詳細(xì)
|
| SHR0302 |
化合物SHR0302 |
1445987-21-2 |
詳細(xì)
|
| Almonertinib |
阿美替尼 |
1899921-05-1 |
詳細(xì)
|
| Almonertinib hydrochloride |
HS-10296 HYDROCHLORIDE |
2134096-03-8 |
詳細(xì)
|
| JND3229 |
JND3229 |
2260886-64-2 |
詳細(xì)
|
| RTC-5 |
RTC-5 |
1423077-49-9 |
詳細(xì)
|
| CCT365623 hydrochloride |
CCT365623 |
2126136-98-7 |
詳細(xì)
|
| SC99 |
SC-99 |
882290-02-0 |
詳細(xì)
|
| JAK/HDAC-IN-1 |
JAK/HDAC-IN-1 |
2284621-75-4 |
詳細(xì)
|
| Erlotinib D6 hydrochloride |
埃羅替尼-D6 鹽酸鹽 |
1189953-78-3 |
詳細(xì)
|
| BMS-599626 Hydrochloride |
BMS-599626 |
873837-23-1 |
詳細(xì)
|
| UC-514321 |
化合物UC-514321 |
299420-83-0 |
詳細(xì)
|
| Gefitinib-based PROTAC 3 |
Gefitinib-based PROTAC 3 |
2230821-27-7 |
詳細(xì)
|
| EGFR-IN-8 |
EGFR-IN-8 |
2407957-87-1 |
詳細(xì)
|
| AS2863619 free base |
AS2863619 free base |
2241300-50-3 |
詳細(xì)
|
| AS2863619 |
AS2863619 |
2241300-51-4 |
詳細(xì)
|
| M-110 |
CS-2124 |
1395048-49-3 |
詳細(xì)
|
| STAT3-IN-3 |
STAT3-IN-3 |
2361304-26-7 |
詳細(xì)
|
| SI-109 |
|
2429877-30-3 |
詳細(xì)
|
| Mavelertinib |
PF-06747775 |
1776112-90-3 |
詳細(xì)
|
| EGFR-IN-11 |
EGFR-IN-11 |
2463200-44-2 |
詳細(xì)
|
| Cenisertib |
R763(AS-703569) |
871357-89-0 |
詳細(xì)
|
| EMI56 |
EMI56 |
2414374-41-5 |
詳細(xì)
|
| BD750 |
2-(2-Benzothiazolyl)-4,5,6,7-tetrahydro-2H-indazol-3-ol |
892686-59-8 |
詳細(xì)
|
| SGI-1776 |
SGI-1776 |
1025065-69-3 |
詳細(xì)
|
| Tesevatinib |
XL-647 |
781613-23-8 |
詳細(xì)
|
| Afatinib impurity 11 |
無中文名稱 |
1402086-20-7 |
詳細(xì)
|
| AG-1478 |
AG1478 |
153436-53-4 |
詳細(xì)
|